However, Supernus Pharmaceuticals is here to correct the record and support adults living with ADHD. The drugmaker recently unveiled a pair of campaigns featuring prominent public figures discussing ...

(NASDAQ:SRPT) plunged to $19.91, down $16.27, or almost 45%, on word of a second death by acute liver failure (ALF) with Elevidys (delandistrogene moxeparvovec), the approved gene therapy for patients ...

Supernus Pharmaceuticals (SUPN) acquires Sage Therapeutics (SAGE), enhancing its CNS portfolio with Zurzuvae's potential.

After rejecting a buyout offer from its partner Biogen, the Cambridge firm is being acquired by Supernus Pharmaceuticals.

Neurology specialist Supernus Pharmaceuticals will snap up Sage Therapeutics, which was once valued at more than $9 billion, ...

After Biogen failed with a takeover bid in January, Supernus has swooped in to acquire the postpartum depression pill ...

Supernus Pharmaceuticals will acquire Sage Therapeutics in a deal worth up to $795 million to gain access to the only ...

Supernus CEO Jack Khattar said the deal adds a “significant fourth growth product to our portfolio and further diversifies ...

Supernus to acquire Sage Therapeutics for $795 million, gaining Zurzuvae and aiming for $200 million in annual cost synergies by expanding its CNS portfolio.

Supernus Pharmaceuticals agreed to buy Sage Therapeutics for $8.50 a share in cash, equal to a total price of about $561 million at closing.

ROCKVILLE/CAMBRIDGE - Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) announced Monday it will acquire Sage Therapeutics, Inc. (NASDAQ:SAGE) in a deal valued at up to $795 million, strengthening its ...